NERV — Minerva Neurosciences Income Statement
0.000.00%
Last trade - 00:00- $27.13m
- $74.85m
Annual income statement for Minerva Neurosciences, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 41.2 | 0 | 0 | 0 | 0 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Total Operating Expenses | 39.3 | 45.4 | 25.2 | 23.1 | 21.8 |
| Operating Profit | 1.85 | -45.4 | -25.2 | -23.1 | -21.8 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | 1.94 | -51.7 | -32.1 | -30 | 1.44 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | 1.94 | -49.9 | -32.1 | -30 | 1.44 |
| Net Income Before Extraordinary Items | |||||
| Net Income | 1.94 | -49.9 | -32.1 | -30 | 1.44 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Dilution Adjustment | |||||
| Diluted Net Income | 1.94 | -49.9 | -32.1 | -30 | 1.44 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | 0.379 | -9.35 | -6.01 | -4.61 | 0.19 |